What are the considerations when selecting a model for influenza drug discovery?

References

• Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med. 2021 Mar;27(3):401–410.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31 391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Past Seasons Vaccine Effectiveness Estimates. US centers for disease control and prevention (CDC). https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html
   Google Scholar
• Govorkova EA, Takashita E, Daniels RS, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020. Antiviral Res. 2022 Apr;200:105281.
   PubMed Web of Science ®Google Scholar
• Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-Emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020 Jan 14 221(3):346–355.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Seong BL. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. Expert Opin Drug Discov. 2019 Feb;14(2):153–168.
   PubMed Web of Science ®Google Scholar
• Yu D, Wang L, Wang Y. Recent advances in application of computer-aided drug design in anti-influenza a virus drug discovery. Int J Mol Sci. 2022 Apr 25;23(9):4738.
   PubMed Web of Science ®Google Scholar
• Bai Y, Jones JC, Wong SS, et al. Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance. Viruses. 2021 Apr 6 13(4):624.
   PubMed Web of Science ®Google Scholar
• Martinez-Sobrido L, DeDiego ML, Nogales A. Reverse genetics approaches for the development of new vaccines against influenza A virus infections. Curr Opin Virol. 2020 Oct;44:26–34.
   PubMed Web of Science ®Google Scholar
• Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and Influenza. Cell. 2020 May 14 181(4):865–876 e12.
   PubMed Web of Science ®Google Scholar
• Bologa CG, Ursu O, Oprea TI. How to prepare a compound collection prior to virtual screening. Methods Mol Biol. 2019;1939:119–138.
   PubMedGoogle Scholar
• Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019 Jun;18(6):463–477.
   PubMed Web of Science ®Google Scholar
• Atkins C, Evans CW, White EL, et al. Screening methods for influenza antiviral drug discovery. Expert Opin Drug Discov. 2012 May;7(5):429–438.
   PubMed Web of Science ®Google Scholar
• Parker CG, Galmozzi A, Wang Y, et al. Ligand and target discovery by fragment-based screening in human cells. Cell. 2017 Jan 26 168(3):527–541 e29.
   PubMed Web of Science ®Google Scholar
• Li Y, Pei J, Lai L. Structure-based de novo drug design using 3D deep generative models. Chem Sci. 2021 Oct 27; 12(41):13664–13675.
   PubMed Web of Science ®Google Scholar
• Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018 Jun 25 8(1):9633.
   PubMedGoogle Scholar
• Caceres CJ, Seibert B, Cargnin Faccin F, et al. Influenza antivirals and animal models. FEBS Open Bio. 2022 Jun;12(6):1142–1165.
   PubMed Web of Science ®Google Scholar
• Sullivan C, Jurcyzszak D, Goody MF, et al. Using Zebrafish models of human influenza a virus infections to screen antiviral drugs and characterize host immune cell responses. J Vis Exp. 2017 Jan 20;(119):55235. DOI:10.3791/55235.
   PubMed Web of Science ®Google Scholar
• Nainu F, Rahmatika D, Emran TB, et al. potential application of Drosophila melanogaster as a model organism in COVID-19-related research. Front Pharmacol. 2020;11:588561.
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe. 2010 Jun 25;7(6):440–451.
   PubMed Web of Science ®Google Scholar
• Jaklevic MC. Flu vaccination urged during COVID-19 pandemic. JAMA. 2020 Sep 8; 324(10):926–927.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li H, Wu M, et al. Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects. Expert Opin Investig Drugs. 2021 Nov;30(11):1159–1167.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Seong BL. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. Expert Opin Drug Discov. 2017 Nov;12(11):1139–1152.
   PubMed Web of Science ®Google Scholar
• Brown JC, Barclay WS, Galiano M, et al. Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding. J Gen Virol. 2020 May;101(5):456–466.
   PubMed Web of Science ®Google Scholar
• Bluhmki T, Bitzer S, Gindele JA, et al. Development of a miniaturized 96-Transwell air-liquid interface human small airway epithelial model. Sci Rep. 2020 Aug 3 10(1):13022.
   PubMed Web of Science ®Google Scholar
• Parra-Rojas C, Nguyen VK, Hernandez-Mejia G, et al. Neuraminidase inhibitors in influenza treatment and prevention – is it time to call it a day? Viruses. 2018 Aug 25 10(9):454.
   PubMed Web of Science ®Google Scholar
• Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020 Apr 2;181(1):102–114.
   PubMed Web of Science ®Google Scholar
• Bachar SC, Mazumder K, Bachar R, et al. A review of medicinal plants with antiviral activity available in Bangladesh and mechanistic insight into their bioactive metabolites on SARS-CoV-2, HIV and HBV. Front Pharmacol. 2021;12:732891.
   PubMed Web of Science ®Google Scholar
• Salampe M, Mamada SS, Evary YM, et al. Promising marine natural products for tackling viral outbreaks: a focus on possible targets and structure-activity relationship. Curr Top Med Chem. 2022 Aug 31; Online ahead of print.
   Google Scholar
• Musarra-Pizzo M, Pennisi R, Ben-Amor I, et al. Antiviral activity exerted by natural products against human viruses. Viruses. 2021 May 4 13(5):828.
   PubMed Web of Science ®Google Scholar